The interim policy covers BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax, even though FDA staff had advised against it. Public Citizen calls the move reckless.
Recap by typeshit. Full story at The Detroit News.
A pharmacist writes that FDA scientists recommended against all seven peptides reviewed, and warns the policy could weaken incentives to run real trials.
The unapproved Lilly drug was confiscated in a dozen enforcement raids, part of a growing crackdown on gray-market retatrutide sellers.
An FDA lawyer explains enforcement discretion, and ASOP Global warns illegal online sellers can now blend in with compliant ones.
KKM says it has seized 759 units of GLP-1 receptor agonist products worth RM405,170 since 2025 in its crackdown on unlicensed sellers.
Prescriptions are required and HHS says this isn't FDA approval. No published human trials show these six peptides work for any condition.
Men's Health argues that wider access to peptides does not automatically make them safer, and looks at where the policy could go from here.
Loading…